EE150 A Budget Impact Analysis of the Introduction of Mosunetuzumab for Treatment of Third- or Higher-Line (3L+) Relapsed or Refractory (R/R) Follicular Lymphoma (FL) in the United States (US)

Abstract

Mosunetuzumab (Mosun), a CD20xCD3 T-cell engaging bispecific antibody, has received US Food and Drug Administration accelerated approval. We conducted a budget impact analysis to assess the impact of introducing Mosun as a 3L+ R/R FL treatment option and to estimate the total cumulative costs per patient in the US.